AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

Phase 2

Active, not recruiting

Conditions: Urinary Bladder Neoplasms

Interventions: Drug: Durvalumab
Drug: Placebo
Drug: Olaparib

First Posted Date: 2018-03-09

Last Posted Date: 2025-05-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 154

Registration Number: NCT03459846

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer

Completed

Conditions: Non Small Cell Lung Cancer

First Posted Date: 2018-03-07

Last Posted Date: 2020-12-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 423

Registration Number: NCT03457220

Locations: 🇨🇳
Research Site, Taipei, Taiwan

A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: AZD9977 Oral suspension (reference)
Drug: AZD9977 capsule
Drug: AZD9977 ER capsule (fastvrate)
Drug: AZD9977 ER capsule (Int. rate)

First Posted Date: 2018-03-01

Last Posted Date: 2018-06-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 13

Registration Number: NCT03450759

Locations: 🇬🇧
Research Site, London, United Kingdom

ADHERE-S (NIS Brilique)

Completed

Conditions: ACS (Acute Coronary Syndrome)

First Posted Date: 2018-02-23

Last Posted Date: 2020-08-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 269

Registration Number: NCT03444012

Locations: 🇷🇸
CHC Bezanijska Kosa, Belgrade, Serbia
🇷🇸
Institute for cardiovascular diseases, Dedinje, Belgrade, Serbia
🇷🇸
CHC Zvezdara, Belgrade, Serbia

and more 6 locations

Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: AZD9977
Other: Placebo

First Posted Date: 2018-02-19

Last Posted Date: 2018-06-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 27

Registration Number: NCT03435276

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants.

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: AZD8154

First Posted Date: 2018-02-19

Last Posted Date: 2019-08-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 78

Registration Number: NCT03436316

Locations: 🇩🇪
Research Site, Berlin, Germany

An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.

Completed

Conditions: Urinary Bladder Cancer

First Posted Date: 2018-02-15

Last Posted Date: 2024-03-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 248

Registration Number: NCT03433924

Locations: 🇨🇳
Research Site, Zhengzhou, China

A Cross-sectional Study of COPD and Symptom Variability in MEA Countries

Completed

Conditions: Chronic Obstructive Pulmonary Disease

First Posted Date: 2018-02-08

Last Posted Date: 2018-06-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 3254

Registration Number: NCT03425760

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Phase 1

Recruiting

Conditions: Brain Neoplasms, Malignant
Leptomeningeal Disease (LMD)
Recurrent Glioblastoma Multiforme
Primary Glioblastoma Multiforme

Interventions: Radiation: Radiation Therapy
Drug: AZD1390

First Posted Date: 2018-02-06

Last Posted Date: 2025-04-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 180

Registration Number: NCT03423628

Locations: 🇬🇧
Research Site, London, United Kingdom

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Phase 1

Completed

Conditions: Advanced Solid Tumours

Interventions: Drug: AZD9150
Drug: Durvalumab
Drug: Cisplatin
Drug: 5-Flourouracil
Drug: Nab-paclitaxel
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2018-02-05

Last Posted Date: 2024-08-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 76

Registration Number: NCT03421353

Locations: 🇺🇸
Research Site, Fairfax, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy